Inhaled aviptadil for the possible treatment of COVID-19 in patients at high risk for ARDS: study protocol for a randomized, placebo-controlled, and multicenter trial

Inhaled aviptadil for the possible treatment of COVID-19 in patients at high risk for ARDS: study protocol for a randomized, placebo-controlled, and multicenter trial

Abstract Background Despite the fast establishment of new therapeutic agents in the management of COVID-19 and large-scale vaccination campaigns since the beginning of the SARS-CoV-2 pandemic in early 2020, severe disease courses still represent a threat, especially to patients with risk factors. Th...

Full description

Bibliographic Details
Main Authors: Maria Boesing, Kristin Abig, Michael Brändle, Martin Brutsche, Emanuel Burri, Björn C. Frye, Stéphanie Giezendanner, Jan C. Grutters, Philippe Haas, Justian Heisler, Fabienne Jaun, Anne B. Leuppi-Taegtmeyer, Giorgia Lüthi-Corridori, Joachim Müller-Quernheim, Reto Nüesch, Wolfgang Pohl, Frank Rassouli, Jörg D. Leuppi
Format: Article
Language:English
Published: BMC 2022-09-01
Series:Trials
Subjects:
Aviptadil
VIP
COVID-19
ARDS
SARS-CoV-2
Online Access:https://doi.org/10.1186/s13063-022-06723-w

Internet

https://doi.org/10.1186/s13063-022-06723-w

Similar Items